Table 2.
Baseline characteristics (at randomization) in all randomized participants
| Characteristics | Tirzepatide MTD (n = 287) | Placebo (n = 292) | Total (n = 579) |
|---|---|---|---|
| Age, mean (s.d.), years | 45.4 (12.6) | 45.7 (11.8) | 45.6 (12.2) |
| Sex, no. (%) | |||
| Female | 181 (63.1) | 183 (62.7) | 364 (62.9) |
| Male | 106 (36.9) | 109 (37.3) | 215 (37.1) |
| Race, no. (%)a | |||
| Asian | 2 (0.7) | 2 (0.7) | 4 (0.7) |
| Black or African American | 31 (10.8) | 32 (11.0) | 63 (10.9) |
| Multiple | 6 (2.1) | 2 (0.7) | 8 (1.4) |
| American Indian or Alaskan | 2 (0.7) | 4 (1.4) | 6 (1.0) |
| White | 246 (85.7) | 252 (86.3) | 498 (86.0) |
| Ethnicity, no. (%)a | |||
| Hispanic or Latino | 151 (52.6) | 161 (55.1) | 312 (53.9) |
| Not Hispanic or Latino | 132 (46.0) | 129 (44.2) | 261 (45.1) |
| Not reported | 4 (1.4) | 2 (0.7) | 6 (1.0) |
| Country | |||
| Argentina | 43 (15.0) | 44 (15.1) | 87 (15.0) |
| Brazil | 59 (20.6) | 60 (20.5) | 119 (20.6) |
| USA | 185 (64.5) | 188 (64.4) | 373 (64.4) |
| Duration of obesity, mean (s.d.), yearsb | 15.4 (11.6) | 14.8 (10.8) | 15.1 (11.2) |
| BMI category, no. (%) | |||
| <27 | 5 (1.7) | 12 (4.1) | 17 (2.9) |
| ≥27 to <30 | 32 (11.1) | 38 (13.0) | 70 (12.1) |
| ≥30 to <35 | 100 (34.8) | 107 (36.6) | 207 (35.8) |
| ≥35 to <40 | 95 (33.1) | 79 (27.1) | 174 (30.1) |
| ≥40 | 55 (19.2) | 56 (19.2) | 111 (19.2) |
| Obesity-related complications, n (%)c | |||
| Hypertension | 95 (33.1) | 104 (35.6) | 199 (34.4) |
| Dyslipidemia | 71 (24.7) | 81 (27.7) | 152 (26.3) |
| ASCVD | 5 (1.7) | 6 (2.1) | 11 (1.9) |
| Polycystic ovarian syndrome | 8 (4.4) | 8 (4.4) | 16 (4.4) |
| Obstructive sleep apnea | 25 (8.7) | 34 (11.6) | 59 (10.2) |
| Osteoarthritis | 43 (15.0) | 48 (16.4) | 91 (15.7) |
| Anxiety/depression | 61 (21.3) | 55 (18.8) | 116 (20.0) |
| NAFLD | 9 (3.1) | 16 (5.5) | 25 (4.3) |
| Asthma or COPD | 21 (7.3) | 31 (10.6) | 52 (9.0) |
| Gout | 6 (2.1) | 9 (3.1) | 15 (2.6) |
| Number of weight-related complications, n (%)c | |||
| 0 | 96 (33.4) | 100 (34.2) | 196 (33.9) |
| 1 | 102 (35.5) | 81 (27.7) | 183 (31.6) |
| 2 | 48 (16.7) | 54 (18.5) | 102 (17.6) |
| 3 | 22 (7.7) | 36 (12.3) | 58 (10.0) |
| 4 | 14 (4.9) | 14 (4.8) | 28 (4.8) |
| ≥5 | 5 (1.7) | 7 (2.4) | 12 (2.1) |
ASCVD, atherosclerotic cardiovascular disease; COPD, chronic obstructive pulmonary disease; NAFLD, non-alcoholic fatty liver disease.
aRace and ethnicity were determined by the participant according to fixed selection categories.
bDuration of obesity was assessed by self-report.
cBaseline medical conditions were assessed through a review of participants’ medical history.